Finally, in patients on multi-injection insulin therapy, a RCT demonstrated that treatment with IDegLira was responsible for a reduction in HbA1c comparable to MDI, with statistically significant lower rates of hypoglycemia; body weight decreased with IDegLira and increased with MDI [15]. The gene discussed is INS; the disease is Hypoglycemia.